ArticleOncotarget2018
Signature program: a platform of basket trials.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer.Cancer medicine · 2025Review
- Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research.Journal of clinical medicine · 2025Article
- Recent advances in the methods and clinical applications of next-generation sequencing in genomic profiling and precision cancer therapy.EXCLI journal · 2025Review
- Bayesian modelling strategies for borrowing of information in randomised basket trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2022Article
- Transcriptomics and solid tumors: The next frontier in precision cancer medicine.Seminars in cancer biology · 2022Review
- Functional Drug Screening in the Era of Precision Medicine.Frontiers in medicine · 2022Review
- When should we order a next generation sequencing test in a patient with cancer?EClinicalMedicine · 2020Review
- Review of precision cancer medicine: Evolution of the treatment paradigm.Cancer treatment reviews · 2020Review
- A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies.Oncotarget · 2020Article
- Basket Designs: Statistical Considerations for Oncology Trials.JCO precision oncology · 2019Review
- Review
- Article
- Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.BMC cancer · 2019Article
- Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer.Oncology letters · 2019Article
- Reporting of master protocols towards a standardized approach: A systematic review.Contemporary clinical trials communications · 2019Article
- Challenges and approaches to implementing master/basket trials in oncology.Blood advances · 2019Article
- Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation.Clinical pharmacology and therapeutics · 2019Article
- Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.Pharmaceutical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Investigating targeted therapies can be challenging due to diverse tumor mutations and slow patient accrual for clinical studies. The Signature Program is a series of 8 phase 2, agent-specific basket protocols using a rapid study start-up approach involving no predetermined study sites. Each protocol evaluated 1 agent (buparlisib, dovitinib, binimetinib, encorafenib, sonidegib, BGJ398, ceritinib, or ribociclib) in patients with solid or hematologic malignancies and an actionable mutation. The primary endpoint of each study was the clinical benefit rate (ie, complete or partial response, or stable disease) at 16 weeks. A total of 192 individual sites were opened in the United States, with a median start-up time of 3.6 weeks. The most common tumor types among the 595 treated patients were colorectal (9.2%), non-small cell lung adenocarcinoma (9.1%), and ovarian (8.4%). Frequent genetic alterations were in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.